Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients [1]

AIDS

Volumn 19, Issue 4, 2005, Pages 447-449

  Campo, Rafael E ^a,b   Lalanne, Rose ^a   Tanner, Thomas J ^a   Jayaweera, Dushyantha T ^a,b   Rodriguez, Allan E ^a,b   Fontaine, Lunie ^b   Kolber, Michael A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INDINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

CLINICAL ARTICLE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MONOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; TOXICITY; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 15944385979     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000161777.38438.ed     Document Type: Letter

References (15)

1. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339:1261-1268.
2. Flandre P, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, et al. Final analysis of the Trilege induction-maintenance trial: results at 18 months. AIDS 2002; 16:561-568.
3. Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash R, Emini EA. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis 2000; 182:758-765.
4. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42:3218-3224.
5. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-F9.
6. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185:599-607.
7. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-7469.
8. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.
9. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon C, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
10. Kahlert C, Hupfer M, Wagels T, Bueche D, Fierz W, Walker UA, Vernazza PL. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection. AIDS 2004; 18:955-957.
11. Arribas JR, Pulido F, Lorenzo A, Delgado R, Blanco A, Miralles P, et al. Simplification to lopinavir/r single-drug HAART: 24 weeks results of a randomized, controlled, open label, pilot clinical trial (OK Study). In: XVth International AIDS Conference. Bangkok, Thailand, 2004 [Abstract TuPeB4486].
12. Pierone G, Mieras J, Kantor C, Bulgin-Coleman D, Shearer J, McCabe J. Lopinavir/r as sole therapy for HIV infection. In: 9th European AIDS Conference. Warsaw, Poland, 2003 [Abstract oral presentation forum 1/5].
13. Gathe JC Jr, Washington MY, Mayberry C, Piot D, Nemecek J. IMANI-1 TC3WP single drug HAART proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HMRT in HIV+ ARV-naive patients - interim analysis of subjects completing final 48 week data. In: XVth International AIDS Conference. Bangkok, Thailand, 2004 [Abstract MoOrB1057].
14. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA panel. JAMA 2002; 288:222-235.
15. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. HIV PoCPfTo. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137:381-433.